Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W23 digital CBT-I sleep therapy at $60/month with 50% better results than sleeping pills; $6.5M total ($6M Initialized/YC/Goodwater seed Feb 2024) treating chronic insomnia psychologically competing with Sleepio.
Stellar Sleep is a United States-based digital sleep therapy platform — backed by Y Combinator (W23) with $6.5 million in total funding including a $6 million seed in February 2024 led by Initialized Capital with Y Combinator, Lombardstreet Ventures, Switch Ventures, Moonfire Ventures, Scrum Ventures, 8vdx, and Goodwater Capital — providing chronic insomnia sufferers with a $60/month mobile app that delivers CBT-I (cognitive behavioral therapy for insomnia), acceptance and commitment therapy, and motivational interviewing through a structured program clinically validated to be 50% more effective than sleeping pills for long-term insomnia resolution. Founded in 2023, Stellar Sleep treats the root psychological and behavioral causes of insomnia rather than masking symptoms with pharmaceutical or supplement approaches.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.